All In Biotech

NDA 021669 · Sage Prods

Chlorhexidine Gluconate

Chlorhexidine Gluconate · Topical

Last checked: Nov 19, 2026Latest source record: Sep 6, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Apr 25, 2005

Approved uses

1

Original approval plus efficacy supplements

Registered trials

551

112 Phase 3, 30 recruiting

FAERS reports

7,708

6,490 serious, 2,709 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 16, 2026.

Uses helps reduce bacteria that can potentially cause skin infection for preparation of skin prior to surgery

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • CHLORHEXIDINE GLUCONATE · CHLORHEXIDINE GLUCONATE 2% · CLOTH, TOPICAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Chlorhexidine Gluconate" as an intervention, any sponsor and status, largest first.

All 551 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue1,899
  • joint swelling1,721
  • rash1,692
  • hypersensitivity1,663
  • impaired healing1,631
  • folliculitis1,619
  • weight increased1,608
  • pain1,585
  • stomatitis1,569
  • arthralgia1,554
  • lower respiratory tract infection1,543
  • glossodynia1,530

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200428
200519
200620
200738
200889
200995
2010151
2011160
2012163
201364
201483
2015131
2016235
2017267
2018297
2019309
2020401
2021676
2022602
2023506
20241,322
20251,535
2026517

Recalls

2 FDA enforcement reports for this application.

  • Aug 18, 2026 · Class II · Ongoing

    Cross Contamination with Other Products

  • Jul 29, 2016 · Class II · Terminated

    CGMP Deviations: potential contamination of products manufactured on the same equipment and lines as the contaminated product.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Chlorhexidine Gluconate (Chlorhexidine Gluconate)

2024 spending

$13.7M

Beneficiaries

1,659,673

2,600,933 claims

Per beneficiary

$8

$0.01 per unit

View as table
YearSpending
2020$11,711,086
2021$13,383,473
2022$14,509,684
2023$14,543,618
2024$13,681,591

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 571 on PubMed

Sponsor: Sage Prods

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.